Kymera Therapeutics Inc (KYMR) stock: analyst predictions for current quarter EPS

After finishing at $39.42 in the prior trading day, Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $37.64, down -4.52%. In other words, the price has decreased by -$1.78 from its previous closing price. On the day, 543257 shares were traded. KYMR stock price reached its highest trading level at $38.66 during the session, while it also had its lowest trading level at $36.76.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Ratios:

Our goal is to gain a better understanding of KYMR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.73 and its Current Ratio is at 4.73. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.

BofA Securities Downgraded its Buy to Neutral on January 03, 2024, whereas the target price for the stock was revised from $45 to $30.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 15 ’24 when Booth Bruce sold 71,764 shares for $40.46 per share. The transaction valued at 2,903,336 led to the insider holds 806,697 shares of the business.

Booth Bruce sold 55,779 shares of KYMR for $2,229,927 on Mar 14 ’24. The Director now owns 819,151 shares after completing the transaction at $39.98 per share. On Mar 13 ’24, another insider, Booth Bruce, who serves as the Director of the company, sold 139,255 shares for $42.23 each. As a result, the insider received 5,880,415 and left with 828,830 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 2.30B and an Enterprise Value of 2.01B. For the stock, the TTM Price-to-Sale (P/S) ratio is 29.27 while its Price-to-Book (P/B) ratio in mrq is 5.30. Its current Enterprise Value per Revenue stands at 25.54 whereas that against EBITDA is -14.02.

Stock Price History:

Over the past 52 weeks, KYMR has reached a high of $45.31, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is 38.13, while the 200-Day Moving Average is calculated to be 24.58.

Shares Statistics:

The stock has traded on average 797.06K shares per day over the past 3-months and 630.71k shares per day over the last 10 days, according to various share statistics. A total of 55.59M shares are outstanding, with a floating share count of 54.16M. Insiders hold about 11.38% of the company’s shares, while institutions hold 90.16% stake in the company. Shares short for KYMR as of Mar 15, 2024 were 8.33M with a Short Ratio of 10.45, compared to 8.4M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.63% and a Short% of Float of 15.27%.

Earnings Estimates

Its stock is currently analyzed by 12 different market analysts. On average, analysts expect EPS of -$0.72 for the current quarter, with a high estimate of -$0.57 and a low estimate of -$0.87, while EPS last year was -$0.7. The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.47 and low estimates of -$0.89.

Analysts are recommending an EPS of between -$1.64 and -$4.16 for the fiscal current year, implying an average EPS of -$3.07. EPS for the following year is -$3.23, with 14 analysts recommending between -$1.91 and -$4.56.

Revenue Estimates

12 analysts predict $14.83M in revenue for the current quarter. It ranges from a high estimate of $23M to a low estimate of $10M. As of the current estimate, Kymera Therapeutics Inc’s year-ago sales were $9.47M, an estimated increase of 56.70% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $12.16M, a decrease of -13.50% less than the figure of $56.70% in the same quarter last year. There is a high estimate of $26.9M for the next quarter, whereas the lowest estimate is $200k.

A total of 15 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $125M, while the lowest revenue estimate was $15.2M, resulting in an average revenue estimate of $58.68M. In the same quarter a year ago, actual revenue was $78.59M, down -25.30% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $72.78M in the next fiscal year. The high estimate is $129.1M and the low estimate is $20M. The average revenue growth estimate for next year is up 24.00% from the average revenue estimate for this year.

Most Popular